BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 20384019)

  • 21. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC; Abu-Alfa AK
    J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gadolinium-associated nephrogenic systemic fibrosis in a 9-year-old boy.
    Foss C; Smith JK; Ortiz L; Hanevold C; Davis L
    Pediatr Dermatol; 2009; 26(5):579-82. PubMed ID: 19840315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nephrogenic systemic fibrosis and gadolinium-containing radiological contrast agents: an update.
    Jalandhara N; Arora R; Batuman V
    Clin Pharmacol Ther; 2011 Jun; 89(6):920-3. PubMed ID: 21471962
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
    Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M
    Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nephrogenic systemic fibrosis: histology and gadolinium detection.
    Thakral C; Abraham JL
    Radiol Clin North Am; 2009 Sep; 47(5):841-53, vi-vii. PubMed ID: 19744599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
    Idée JM; Port M; Dencausse A; Lancelot E; Corot C
    Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nephrogenic systemic fibrosis: is gadolinium to be blamed?
    Jikki PN
    J Assoc Physicians India; 2008 Nov; 56():915-6. PubMed ID: 19263697
    [No Abstract]   [Full Text] [Related]  

  • 28. [Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].
    Varela CU; Prieto-Rayo JC
    Rev Med Chil; 2014 Dec; 142(12):1565-74. PubMed ID: 25693439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Nephrogenic systemic fibrosis and use of MR contrast media].
    Christiansen RE; Sviland L; Sekse I; Svarstad E
    Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gadolinium and systemic fibrosis: guilt by association.
    Kay J; Czirják L
    Ann Rheum Dis; 2010 Nov; 69(11):1895-7. PubMed ID: 20959325
    [No Abstract]   [Full Text] [Related]  

  • 31. Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network.
    Stratta P; Canavese C; Quaglia M; Fenoglio R
    Rheumatology (Oxford); 2010 Apr; 49(4):821-3. PubMed ID: 20032228
    [No Abstract]   [Full Text] [Related]  

  • 32. Focus on contrast-associated nephrogenic systemic fibrosis.
    Partain CL
    J Magn Reson Imaging; 2009 Dec; 30(6):1231-2. PubMed ID: 19938033
    [No Abstract]   [Full Text] [Related]  

  • 33. Special issue: nephrogenic systemic fibrosis.
    Leiner T; Kucharczyk W
    J Magn Reson Imaging; 2009 Dec; 30(6):1233-5. PubMed ID: 19938034
    [No Abstract]   [Full Text] [Related]  

  • 34. Nephrogenic systemic fibrosis.
    Bardin T; Richette P
    Curr Opin Rheumatol; 2010 Jan; 22(1):54-8. PubMed ID: 19881349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk.
    Nicholas BA; Vricella GJ; Smith M; Passalacqua M; Gulani V; Ponsky LE
    Can J Urol; 2012 Feb; 19(1):6074-80. PubMed ID: 22316507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Nephrogenic systemic fibrosis: a severe complication of use to gadolinium in patients with kidney failure].
    Mundim JS; Lorena Sde C; Abensur H; Elias RM; Moysés RM; Castro MC; Romão Júnior JE
    Rev Assoc Med Bras (1992); 2009; 55(2):220-5. PubMed ID: 19488662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nephrogenic systemic fibrosis developed after recovery from acute renal failure: gadolinium as a possible aetiological factor.
    Lu CF; Hsiao CH; Tjiu JW
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):339-40. PubMed ID: 18573157
    [No Abstract]   [Full Text] [Related]  

  • 38. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
    Heverhagen JT; Krombach GA; Gizewski E
    Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis.
    Abraham JL; Edward M
    AJR Am J Roentgenol; 2009 Oct; 193(4):W354; author reply W355. PubMed ID: 19770307
    [No Abstract]   [Full Text] [Related]  

  • 40. Nephrogenic systemic fibrosis and the role of gadolinium contrast media.
    van der Molen AJ
    J Med Imaging Radiat Oncol; 2008 Aug; 52(4):339-50. PubMed ID: 18811757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.